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Abstract:
OBJECTIVE/BACKGROUND: Several studies have yielded conflicting results 
as to whether testosterone treatment increases cardiovascular risk. Recent 
results from the placebo-controlled Cardiovascular Trial of the Testosterone 
Trials showed that testosterone treatment of older men with low 
testosterone was associated with greater progression of non-calcified plaque.
We sought to evaluate the effect of anthropometric measures and 
biomarkers on coronary artery plaque progression in individuals in the 
Testosterone Trial. 
Methods: The Testosterone Trials were a coordinated set of seven double-
blinded, placebo-controlled trials. The Cardiovascular Trial included 170 men 
aged 65 years or older with low testosterone and no contraindication to 
coronary computed tomographic angiography (CCTA). Participants received 
testosterone gel dose-adjusted to maintain the testosterone level in the 
normal range for young men, or placebo gel for 12 months. The primary 
outcome was change in non-calcified coronary artery plaque volume from 
baseline to 12 months, as determined by CCTA. We also assayed several 
markers of cardiovascular risk and analyzed each marker individually in a 
model that included the binary factors for age and testosterone level, the 
marker by treatment interaction, and the baseline value of non-calcified 
plaque as predictive variables and change in non-calcified plaque as the 
dependent variable.  
RESULTS: Of 170 enrollees, 138 (73 testosterones, 65 placebo) completed 
the study and were available for the primary analysis. Among the 138 men, 
the mean (SD) age was 71.2 (5.7) years, 81% were white. Of 9 markers 
evaluated, none showed a significant association with the change in non-
calcified plaque volume, but a significant interaction between treatment and 
waist-hip ratio p-0.0014) indicated that this variable influences the 
testosterone effect on non-calcified plaque volume.  The statistical model 
indicates that every 0.1 change in the waist-hip ratio increases the 
testosterone-induced 12-month change in non-calcified plaque volume by 
26.96 mm3 (95% confidence interval 7.72, 46.20).  
CONCLUSIONS:
Among older men with low testosterone treated with testosterone for one 
year, greater waist-hip ratio was associated with greater non-calcified plaque
progression, as measured by coronary computed tomographic angiography. 
Introduction:
Lower serum testosterone concentration has been associated with adverse 
cardiovascular disease (CVD) outcomes1,2. There are conflicting reports 
regarding the effect of testosterone treatment on CVD risk. Some 
retrospective studies reported more CVD events in men taking testosterone, 
while others did not3-7. The Testosterone Trials (TTrials) comprised seven 
coordinated placebo-controlled clinical trials designed to assess the effects of
testosterone treatment in older men who had low testosterone 
concentrations for no apparent reason other than age8. In the Cardiovascular
Trial, testosterone treatment for one year compared with placebo was 
associated with significantly greater progression of coronary artery non-
calcified plaque volume measured by serial coronary computed tomography 
angiography (CCTA)9.
Serum markers such as total cholesterol, HDL, LDL and hemoglobin A1C,  
have been recognized as significant risk factors for developing coronary 
artery plaque and future CVD events10,11. There are contradictory reports 
about the association of biomarkers and extent, progression of 
atherosclerosis and coronary events12-14.Inflammatory markers such as CRP 
have been reported to be associated with plaque progression in some 
studies15,16, other reports found no association17,18. Anthropometric measures 
such as Waist-Hip ratio and Waist Circumference are predictors of 
myocardial infarction risk19,20. Abdominal obesity can lead to increases in 
insulin and glucose levels and is a central feature of metabolic syndrome. 
Several observational studies have shown link of low endogenous sex 
hormones and metabolic syndrome21-23.  One large cross-sectional study 
reported that higher testosterone and sex hormone binding globulin levels in
older men were independently associated with reduced risk of metabolic 
syndrome and higher insulin sensitivity24.  
The aim of the current study is to evaluate the impact of baseline 
anthropometric measures and cardiovascular biomarkers on the progression 
of coronary artery plaque volume in the 138 men who participated in the 
Cardiovascular Trial of the TTrials.  We also assessed the interaction of 
anthropometric measures and cardiovascular biomarkers with testosterone 
treatment and its impact on plaque progression as measured by CCTA to 
determine whether any of these measures influenced the effect of 
testosterone on plaque progression.
METHODS
Study Design
The TTrials comprised seven double-blind, placebo-controlled randomized 
controlled trials. The overall study design of TTrials, as well that of 
Cardiovascular Trial, has been published8,25.  To qualify for the TTrials overall,
a participant had to qualify for at least 1 of 3 main trials (Sexual Function 
Trial, Physical Function Trial, and Vitality Trial).  Qualified men could also 
participate in any of other trials, if respective criteria were met. The 
participants were allocated to receive testosterone or placebo gel for 1 
year8,9. Institutional review boards of all participating sites approved TTrials 
and Cardiovascular Trial protocols. All participants provided written consent. 
Trial conduct and participant safety was supervised by an independent 
safety and data monitoring board. 
Participants
The TTrials included men > 65 years’ old who had symptoms and objective 
evidence of low libido, physical dysfunction and/or low vitality, serum 
testosterone levels that averaged < 275 ng/dL on 2 morning samples. Men 
who were at moderate or high risk for prostate cancer, who had had a 
myocardial infarction within the previous 3 months, or had systolic blood 
pressure >160 mm Hg or diastolic blood pressure >100 mm Hg, were 
excluded8. 
Exclusion criteria specifically for the Cardiovascular Trial included  
circumstances that either made coronary artery CT angiography (CCTA) 
technically unfeasible (inability to hold breath for 10 seconds, a prior 
diagnosis of tachycardia or irregular heart rhythm [e.g., atrial fibrillation], 
weight >136 kg, or history of coronary artery bypass graft surgery) or 
increased risk of performing the CCTA (estimated glomerular filtration rate 
<60 mL/min/1.73 m2 or known allergy to iodinated contrast)9,25.
Testosterone Treatment:
Participants were assigned to receive either testosterone as a 1 % gel in a 
pump bottle (AndroGel) or placebo gel by a double-blinded method for one 
year. The initial dose was 5 g/d and was adjusted to maintain the serum 
concentrations within normal range for young men (280-873 ng/dL) 
measured at central laboratory (Quest Clinical Trials) at months 1, 2, 3, 6, 
and 9. Whenever dose adjustments were made in a man receiving 
testosterone treatment, the dose was changed in a man receiving placebo as
well to maintain blinding8.
Assessments:
The concentrations of cardiovascular biomarkers were measured on serum 
samples drawn at baseline and months 3 and 12 and stored at -80 C. These 
assays were performed at the  Laboratory for Clinical Biochemistry Research,
University of Vermont and University of Minnesota, as described previously7,9.
At months 3, 6, 9, and 12, clinical variables were measured.
Details of coronary artery plaque volume by CCTA assessment have been 
published25.  In brief, coronary artery plaque volume was assessed by CCTA 
at 9 of the 12 TTrials clinical sites.  Pre-contrast scans for evaluation of 
coronary artery calcium density and post contrast scans for evaluation of 
coronary artery plaque volume were performed at baseline and 12 months. 
Scans were assessed at a central reading center (Harbor-UCLA Medical 
Center) by readers  who were blinded both to treatment group and date of 
scan. Quantitative plaque assessment was conducted according to a  
previously defined protocol26 using semi-automated plaque analysis software
(QAngioCT Research Edition Version 2.0.5; Medis Medical Imaging Systems). 
Based on the guidelines of the Society of Cardiovascular Computed 
Tomography, 17-segment coronary artery model vessels greater than 1.5 
mm were evaluated27. The volumes of four types of coronary artery plaque 
(low attenuation, fibrous-fatty, fibrous, and dense calcified) were calculated 
by Hounsfield unit threshold.  The primary outcome was change in non-
calcified plaque volume from baseline to month 12. Non-calcified plaque was
defined as the sum of the fibrous, fibrous fatty and low attenuation plaque.  
secondary outcomes were change in calcified plaque volume, and change in 
coronary artery score.  Details of intra- and inter-observer variability have 
been published. The intra-class correlations (ICCs) and Coefficient of 
Variation (CVs) were 0.99 and 7.8 % for intra-observer variability 
respectively. ICC and CV was 0.95 and 19.9 % for inter-observer variability 
respectively9.
Statistical Analyses
 The following markers were available for study: total cholesterol; non-HDL 
cholesterol; HDL; LDL; triglycerides; HgA1c; glucose, insulin; HOMA; d-dimer; 
troponin; CRP; Il-6; weight; BMI; waist/hip ratio.  We evaluated the intercorrelation 
of the baseline values of these markers, separately within groups where substantial 
intercorrelation was expected: lipid markers, metabolic markers, markers of 
inflammation, and clinical markers.  We then excluded from further study the 
marker showing correlation > 0.5 with the most other markers, and then eliminated
any marker with correlation > 0.5 with the selected marker from further 
consideration.  We retained any other markers with correlation < 0.5 with the 
selected marker.  If two markers showed high correlation with the same number of 
other markers, we selected the one with the lowest correlation with the remaining 
markers.  
We tested each selected marker separately in a regression model, including 
treatment as a covariate as well as age (over or under 75), baseline testosterone 
(over or under 200 ng/ml) and an interaction term of the marker with treatment.  
Any variable showing a significant association with the change in plaque volume 
after adjusting for multiple comparisons using the Holm procedure28 was to be 
included in a multivariable model, assessing all potentially predictive variables 
simultaneously.  
 Secondary analyses included testing association of the selected markers with 
change in calcified plaque volume and with coronary artery calcium score, using the
same approach as above.
Results
The baseline characteristics of the participants in the Cardiovascular Trial 
were previously reported (9). At baseline, the mean (SD) age was 71.2 (5.7) 
years.  The majority of participants were white (81%) and had relatively high 
rates of cardiovascular risk factors, including hypertension, hyperlipidemia, 
obesity, and diabetes.  At baseline the mean BMI was (3.8) in the 
testosterone group and 30 (3.5) in the placebo group; mean weight was 94 
kg and the mean waist-hip ratio was 1.0 in each treatment group.   The 
calculated 10-year risk of cardiovascular events was relatively high as well (a
mean risk of 27% [95% CI, 6.4%-47.6%] in the placebo group and 24% [95% 
CI 2.6%-45.4%] in the testosterone group. 
Of the 17 markers initially evaluated, 9 remained for further study after 
removing those that were highly correlated with other markers, as described 
above.  These 9 markers were HDL cholesterol, non-HDL cholesterol, D-
dimer, Il-6, CRP, insulin, HgbA1C, weight and waist-hip ratio (Table-1). 
Among these 9 measures, only the baseline waist-hip ratio interaction with 
treatment showed a significant association with the progression of non-
calcified plaque volume at 12 months, (Table 2, Figure 1).  Because it was 
the interaction term that met the threshold based on the multiple 
comparisons adjustment (p=0.0014 compared to threshold value from the 
Holm multiple comparisons procedure of 0.0056), we evaluated waist-hip 
ratio separately for the two treatment groups.  The association was seen only
in the testosterone group (p=0.007).  The model indicates that for every 0.1 
change in the waist-hip ratio, the effect of testosterone on the 12-month 
change in non-calcified plaque volume would increase by 26.96 mm3 (95% 
confidence interval 7.72, 46.20).  (The baseline values of waist-hip ratio 
ranged from 0.9 to 1.2). 
The only variable to show a significant association with change in calcified plaque
volume was D-dimer, and the significant finding was only for the interaction term.
Further investigation showed that the interaction effect appeared to be based on
one or two extreme values in each treatment group.   None of the cardiovascular
risk markers were statistically significantly associated with change in CAC
score when applying the multiple comparisons correction.  
DISCUSSION:
We report that in older hypogonadal men participating in the Cardiovascular 
Trial of the TTrials there was a significant association between baseline 
waist-hip ratio and progression of non-calcified coronary artery plaque 
volume measured by coronary artery CT angiography after one year of 
testosterone treatment.  Larger waist-hip ratios were associated with greater
progression of non-calcified plaque in men taking testosterone.
Visceral adipose tissue decreases insulin sensitivity and promotes 
dyslipidemia and hypertension29,30. Visceral adipose tissue stores can be 
measured by CT, DXA or MRI but these modalities are too expensive and 
time consuming for day-to-day use 31,32. WHR is closely related to visceral fat 
and commonly measured in clinical practice33.  Meta-analyses of 28,114 
patients from 15 prospective studies showed that for every 0.01 increase in 
WHR, there was a 5 % increase in risk of future CVD events 33. Our data 
indicate that for every 0.1 increase in waist hip ratio, there was 26 mm3 
greater increase in progression of non-calcified plaque volume in patients 
treated with testosterone replacement therapy. 
Non-calcified plaque volumes as assessed by cardiac CCTA has been 
associated with CVD events. In a large single center trial by Zu et al34, the 
cumulative probability of 3-year MACE increased across the strata for cardiac
CT plaque, with non-calcified plaque having highest probability, 37.7%.  
WHR and waist circumference, measures of central obesity or abdominal 
obesity, have been associated with reduced total testosterone levels35,36.  A 
mechanism that may account for this inverse relationship involves strong 
association of central obesity and excess secretion of cortisol, potentially 
mediated through suppression of testosterone production via the 
hypothalamic-pituitary axis37.  Another plausible mechanism of decreased 
testosterone in obese individuals is increased aromatase activity in visceral 
adipose tissue, which leads to higher conversion of testosterone to 
estradiol38. Androgen deprivation therapy, as given to patients with prostate 
cancer, has shown to significantly increase BMI, total weight, body fat mass 
and decrease in lean body mass39,40. Hence, several studies have 
investigated the hypothesis that testosterone replacement therapy may 
decrease visceral fat stores and improve the metabolic profile in men. 
However, there are conflicting reports on effects of testosterone replacement
on visceral fat. Some studies reported testosterone replacement therapy 
decreases visceral fat, while other showed no association41,42.  In a study of 
261 patients in a prospective longitudinal registry, testosterone replacement 
was associated with a significant reduction in obesity parameters (e.g. WC, 
BMI) and cholesterol values over the 5-year study period43. However, 
randomized controlled clinical trials reported no impact of testosterone 
replacement on weight, BMI and metabolic syndrome4144.  A previous paper 
from the TTrials also did not show any changes in WHR, WC and BMI in men 
treated with testosterone for 12 months compared to those treated with 
placebo7. 
These results warrant further investigation of the interaction of visceral 
adipose tissue stores and testosterone treatment. To our knowledge, no 
other studies have examined the interaction of testosterone replacement 
therapy and central obesity on CVD outcomes.  The strengths of our trial 
included requiring all men to have unequivocally low testosterone at 
baseline, a placebo-controlled design and blinded central review of baseline 
and 12 month scans.  An important limitation of our study is use of a 
surrogate marker of heart disease, non-calcified plaque, and not a clinical 
outcome. Another limitation is that the results apply only to men >65 with 
low testosterone9.
 
We conclude that older men with higher WHR receiving testosterone 
treatment may experience greater increases in noncalcified coronary plaque 
volume than treated men with lower WHR.  Future trials should evaluate the 
interaction of testosterone treatment and surrogate markers of abdominal 
obesity and visceral fat stores. 
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